Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin

Journal of Experimental Medicine

Volumn 203, Issue 2, 2006, Pages 401-412

  Dunn, Shannon E ^a   Youssef, Sawsan ^a   Goldstein, Matthew J ^a   Prod'homme, Thomas ^b   Weber, Martin S ^b   Zamvil, Scott S ^b   Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ATORVASTATIN; CYTOKINE; DNA; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GGTI 298; ISOPRENOID; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MYELIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN C FOS; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SYNAPTOPHYSIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL FATE; CELL MEMBRANE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPLETION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PATHOGENICITY; PRECURSOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DNA BINDING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTEROL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; PROTEIN ISOPRENYLATION; PYRROLES; RAS PROTEINS; RHOA GTP-BINDING PROTEIN; TERPENES; TH1 CELLS; TH2 CELLS;

EID: 33344475402     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20051129     Document Type: Article

References (45)

1. Vollmer, T., L. Key, V. Durkalski, W. Tyor, and J. Corboy. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 363:1607-1608.
2. McCarey, D.W., I.B. McInnes, R. Madhok, R. Hampson, O. Scherbakov, I. Ford, H.A. Capell, and N. Sattar. 2004. Trial of atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 363:2015-2021.
3. Neuhaus, O., O. Stuve, S.S. Zamvil, and H.-P. Hartung. 2004. Are statins a treatment option for multiple sclerosis. Lancet Neurol. 3:369-371.
4. Stanislaus, R., K. Pahan, A.K. Singh, and I. Singh. 1999. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 269:71-74.
5. Youssef, S., O. Stuve, J.C. Patarroyo, P.J. Ruiz, J.L. Radosevich, E.M. Hur, M. Bravo, D. Mitchell, R.A. Sobel, L. Steinman, and S.S. Zamvil. 2002. The HMG-CoA reductase inhibitor atorvastatin, promotes Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:78-84.
6. Aktas, O., S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, and F. Zipp. 2003. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197:725-733.
7. Greenwood, J., C.E. Walters, G. Pryce, N. Kanuga, E. Beraud, D. Baker, and P. Adamson. 2003. Lovastatin inhibits brain endothelial Rho-mediated lymphocyte migation and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17:905-907.
8. Nath, N., S. Giri, R. Prasad, A.K. Singh, and I. Singh. 2004. Potential targets of 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor for multiple sclerosis therapy. J. Immunol. 172:1273-1286.
9. Leung, B.P., N. Sattar, A. Crilly, M. Prach, D.W. McCarey, H. Payne, R. Madhok, C. Campbell, J.A. Gracie, F.Y. Liew, and I.B. McInnes. 2003. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170:1524-1530.
10. Gegg, M.E., R. Harry, D. Hankey, H. Zambarakji, G. Pryce, D. Baker, P. Adamson, V. Calder, and J. Greenwood. 2005. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J. Immunol. 174:2327-2335.
11. Shimada, K., K. Miyauchi, and H. Daida. 2004. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation. 109:e213-e214.
12. Topol, E.J. 2004. Intensive statin therapy-a sea change in cardiovascular prevention. N. Engl. J. Med. 350:1562-1564.
13. Goldstein, J.L., and M.S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343:425-430.
14. Grunler, J., J. Ericsson, and G. Dallner. 1994. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone, and prenylated proteins. Biochim. Biophys. Acta. 1212:259-277.
15. Weitz-Schmidt, G., K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada, and U. Hommel. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:687-692.
16. + T cells. J. Immunol. 170:2427-2434.
17. Ownby, S.E., and R. Hohl. 2002. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids. 37:185-192.
18. Balamuth, F., D. Leitenberg, J. Unternaechrer, I. Mellman, and K. Bottomly. 2001. Distinct patterns of membrane microdomain partitioning in Th1 and Th2 cells. Immunity. 15:729-738.
19. Ghittoni, R., L. Patrussi, K. Pirozzi, M. Pellegrini, P.E. Lazzerini, P.L. Capecchi, F.L. Pasini, and C.T. Baldari. 2005. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 19:605-607.
20. Vaidya, S., R. Bostedor, M.M. Kurtz, J.D. Bergstrom, and V.S. Bansal. 1998. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthetase inhibitor Zaragozic Acid A. Arch. Biochem. Biophys. 355:84-92.
21. Zhang, F.L., and P.J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:241-269.
22. Cantrell, D.A. 2003. GTPases and T cell activation. Immunol. Rev. 192:122-130.
23. Goldman, F., R.J. Hohl, J. Crabtree, K. Lewis-Tibesar, and G. Koretzky. 1996. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood. 88:4611-4619.
24. Holstein, S.A., C.L. Wohlford-Lenane, and R.J. Hohl. 2002. Consequences of mevalonate depletions: differential transcriptional, translational, and posttranslational upregulation of Ras, Rap1a, RhoA, and RhoB. J. Biol. Chem. 277:10678-10682.
25. Badou, A., M. Savignac, M. Moreau, C. Leclerc, G. Foucras, G. Cassar, P. Paulet, D. Lagrange, P. Druet, J.C. Guery, and L. Pelletier. 2001. Weak TCR stimulation induces a calcium signal that triggers IL-4 synthesis, stronger TCR stimulation induces MAP kinases that control IFN-γ production. Eur. J. Immunol. 31:2487-2496.
26. + cells into effector Th1 and Th2 cells. Microbes Infect. 1:43-50.
27. Lobell, R.B., C.A. Omer, M.T. Abrams, H.G. Bhimnathwala, M.J. Brucker, C.A. Buser, J.P. Davide, S.J. deSolms, C.J. Dinsmore, M.S. Ellis-Hutchings, et al. 2001. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61:8758-8768.
28. Kohl, N.E., C.A. Omer, M.W. Conner, N.J. Anthony, J.P. Davide, S.J. deSolms, E.A. Giuliani, R.P. Gomez, S.L Graham, and K. Hamilton. 1995. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1:792-797.
29. Mach, F. 2004. Statins as immunomodulatory agents. Circulation. 109:II15-II17.
30. Bellosta, S., N. Ferri, F. Bernini, R. Paoletti, and A. Corsini. 2000. Non-lipid related effects of statins. Ann. Med. 32:164-176.
31. Mo, H., and C.E. Elson. 2004. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med (Maywood). 229:567-585.
32. Liao, J.K. 2002. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110:285-288.
33. Layer, K., G. Lin, A. Nencioni, W. Hu, A. Schmucker, A.N. Antov, X. Li, S. Takamatsu, T. Chevassut, N.A. Dower, et al. 2003. Autoimmunity as a consequence of a spontaneous mutation in Rasgrp 1. Immunity. 19:243-255.
34. Dumont, F.J., M.J. Staruch, P. Fischer, C. DaSilva, and R. Camacho. 1998. Inhibition of T cell activation by pharmacological disruption of the MEK1/ERK kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J. Immunol. 160:2579-2589.
35. Naderi, S., R. Blomhoff, J. Myklebust, E.B. Smeland, B. Erikstein, K.R. Norum, and H.K. Blomhoff. 1999. Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis. Exp. Cell Res. 252:144-153.
36. Vogt, A., Y. Qian, T.F. McGuire, A.D. Hamilton, and S.M. Sebti. 1996. Protein geranylgeranylation, but not farnesylation is required for the G1 to S transition in mouse fibroblasts. Oncogene. 13:1991-1999.
37. Bergstrom, J.D., M.M. Kurtz, D.J. Rew, A.M. Amend, J.D. Karkas, R.G. Bostedor, V.S. Bansal, C. Dufresne, F.L. VanMiddlesworth, and O.D. Hensens. 1993. Zaragozic acids: a family of metabolites that are picomolar competitive inhibitors of squalene synthetase. Proc. Natl. Acad. Sci. USA. 90:80-84.
38. Hardardottir, I., A.H. Moser, R. Memon, C. Grunfeld, and K.R. Feingold. 1994. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res. 13:161-166.
39. Memon, R.A., I. Shechter, A.H. Moser, J.K. Shigenaga, C. Grunfeld, and K.R. Feingold. 1997. Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. J. Lipid Res. 38:1620-1629.
40. Hardardottir, F., J.L. Baron, and C.A. Janeway Jr. 1995. T cells with two functional antigen-specific receptors. Proc. Natl. Acad. Sci. USA. 92:354-358.
41. Pedotti, R., J.J. DeVoss, S. Youssef, D. Mitchell, J. Wedemeyer, R. Madanat, H. Garren, P. Fontoura, M. Tsai, S.J. Galli, et al. 2003. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc. Natl. Acad. Sci. USA. 100:1867-1872.
42. Heider, J.G., and R.L. Boyett. 1978. The picomole determination of free and total cholesterol in cells in culture. J. Lipid Res. 19:514-518.
43. Karnell, F.G., R.J. Brezski, L.B. King, M.A. Silverman, and J.G. Monroe. 2005. Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling. J. Biol. Chem. 280:25621-25628.
44. Corsini, A., C.C. Farnsworth, P. McGeady, M.H. Gelb, and J.A. Glomset. 1999. Incorporation of radiolabeled prenyl alcohols and their analogs into mammalian cell proteins. Methods Mol. Biol. 116:125-144.
45. Smith, K., B. Seddon, M.A. Purhboo, R. Zamoyska, A.G. Fisher, and M. Merkenschlager. 2001. Sensory adaptations in naive peripheral CD4 T cells. J. Exp. Med. 194:1253-1262.